Amlashi F, Tritos N
Endocrine. 2016; 52(3):427-40.
PMID: 26792794
DOI: 10.1007/s12020-016-0863-3.
Ashton H, Millman J, Telford R, Thompson J, Davies T, Hall R
Br J Clin Pharmacol. 2012; 3(4):523-31.
PMID: 22216490
PMC: 1428921.
DOI: 10.1111/j.1365-2125.1976.tb04871.x.
de Bruin C, Feelders R, Lamberts S, Hofland L
Rev Endocr Metab Disord. 2008; 10(2):91-102.
PMID: 18642088
DOI: 10.1007/s11154-008-9082-4.
Lindholm J
Pituitary. 2006; 9(1):5-10.
PMID: 16703403
DOI: 10.1007/s11102-006-7557-4.
Thanabalasingham G, Karavitaki N, Cudlip S, Wass J
Endocrine. 2005; 28(1):3-8.
PMID: 16311405
DOI: 10.1385/ENDO:28:1:003.
Acromegaly: historical perspectives and current therapy.
Jane Jr J, Thapar K, Laws Jr E
J Neurooncol. 2002; 54(2):129-37.
PMID: 11761430
DOI: 10.1023/a:1012949214960.
The epidural and intrathecal administration of somatotrophin-release inhibiting factor: native and synthetic analogues.
Beltrutti D, Moessinger S, Varrassi G
Curr Rev Pain. 2000; 4(1):82-90.
PMID: 10998719
DOI: 10.1007/s11916-000-0013-7.
Oral glucose tolerance test: an inhibitory or a stimulatory input to growth hormone secretion?.
Valcavi R
J Endocrinol Invest. 1996; 19(4):253-5.
PMID: 8862507
DOI: 10.1007/BF03349877.
Effect of 4 weeks of octreotide treatment on prolactin, thyroid stimulating hormone and thyroid hormones in acromegalic patients. A double blind placebo-controlled cross-over study.
Andersen M, Hansen T, Bollerslev J, Bjerre P, Schroder H, Hagen C
J Endocrinol Invest. 1995; 18(11):840-6.
PMID: 8778155
DOI: 10.1007/BF03349830.
Bromocriptine therapy in acromegaly. A long-term review of 35 cases.
Sachdev Y, Gopal K, Garg V
Postgrad Med J. 1981; 57(666):210-6.
PMID: 7027229
PMC: 2424984.
DOI: 10.1136/pgmj.57.666.210.
An in vivo model for testing somatostatin suppression of growth hormone release in sheep.
Redekopp C, Barrier L, Livesey J, DONALD R
J Endocrinol Invest. 1980; 3(3):237-41.
PMID: 6153047
DOI: 10.1007/BF03348269.
Suppression and stimulation of growth hormone release in sheep by somatostatin analogs.
Redekopp C, Livesey J, DONALD R
J Endocrinol Invest. 1984; 7(4):277-81.
PMID: 6150052
DOI: 10.1007/BF03351002.
Direct effects of catecholamines, thyrotropin-releasing hormone, and somatostatin on growth hormone and prolactin secretion from adenomatous and nonadenomatous human pituitary cells in culture.
Ishibashi M, Yamaji T
J Clin Invest. 1984; 73(1):66-78.
PMID: 6140273
PMC: 424971.
DOI: 10.1172/JCI111208.
Ultrastructural changes rapidly induced by somatostatin may inhibit prolactin release in estrogen-primed rat adenohypophysis.
Saunders S, Reifel C, Shin S
Cell Tissue Res. 1983; 232(1):21-34.
PMID: 6136330
DOI: 10.1007/BF00222371.
Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
de Quijada M, Redding T, Coy D, Torres-Aleman I, Schally A
Proc Natl Acad Sci U S A. 1983; 80(11):3485-8.
PMID: 6134284
PMC: 394069.
DOI: 10.1073/pnas.80.11.3485.
Somatostatin inhibits multireceptor stimulation of cyclic AMP formation and corticotropin secretion in mouse pituitary tumor cells.
Heisler S, Reisine T, Hook V, Axelrod J
Proc Natl Acad Sci U S A. 1982; 79(21):6502-6.
PMID: 6128732
PMC: 347155.
DOI: 10.1073/pnas.79.21.6502.
Effect of somatostatin on gastrin, insulin and glucagon secretion in two patients with Zollinger-Ellison syndrome.
Fallucca F, Fave G, Giangrande L, del Balzo P, De Magistris L, Carratu R
J Endocrinol Invest. 1981; 4(4):451-3.
PMID: 6120969
DOI: 10.1007/BF03348310.
The interrelationship of somatostatin and guanylate cyclase activity.
Vesely D
Mol Cell Biochem. 1980; 32(3):131-4.
PMID: 6110170
DOI: 10.1007/BF00227439.
Growth hormone release inhibiting hormone in acromegaly.
Besser G, Mortimer C, Carr D, Schally A, Coy D, Evered D
Br Med J. 1974; 1(5904):352-5.
PMID: 4594581
PMC: 1633619.
DOI: 10.1136/bmj.1.5904.352.
Editorial: Assessment and management of acromegaly.
Br Med J. 1974; 4(5944):549-50.
PMID: 4434135
PMC: 1612698.
DOI: 10.1136/bmj.4.5944.549.
